DOCSLIB.ORG

DIOVAN Vs Captopril

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
DIOVAN Vs Captopril Cardiac Protection across the cardiac continuum Dong-Ju Choi, MD, PhD College of Medicine Seoul National University Renin Angiotensin Cascade ↑ Nitric oxide (NO) Angiotensinogen •t-PA Renin •Cathepsin G A I ↑ Bradykinin CAGE •Tonin ACE Cathepsin G Chymase Degradation A II products ACEI site of action AT1 receptor AT2 receptor • Hypertrophy/proliferation • Antiproliferation • Vasoconstriction • NO Release • Aldosterone release • Differentiation • Antidiuretic hormone release • Vasodilation de Gasparo M, et al. Hypertension. Pathophysiology, Diagnosis, and Management. 2nd ed. New York, NY: Raven Press; 1995:1695–1720. Dzau VJ. J Hypertens. 1989;7:933-936. Pathophysiologic Effects of Angiotensin II Abnormal ↑PAI-1/ vasoconstriction thrombosis ↑Contractility Platelet aggregation Activate SNS Superoxide AngiotensinAngiotensin IIII production ↑Aldosterone Vascular smooth ↑Vasopressin muscle growth ↑Endothelin Myocyte growth ↑Collagen Burnier M, Brunner HR. Lancet. 2000;355:637–645. Adverse Effects of RAS on CV System Vascular change 1. Vascular remodeling 2. Endothelial dysfunction 3. Inflammation Myocardial damage 1. Myocyte sequestration 2. Myocyte isolation Increase BP Ang II Vascular Remodeling AngII-induced Inflammation The inflammatory response by AngII: 1) Increase in vascular permeability, 2) Infiltration of leukocytes, and 3) Tissue remodeling. Myocardial Damage by RAS 1. Myocyte sequestration • Hypertrophy • Apoptosis • Necrosis 2. Myocyte isolation • Interstitial fibrosis • Conduction disturbance Blocking RAS is critical to prevent 1. Vascular change (Vascular remodeling, endothelial dysfunction and inflammation) and 2. Myocardial damage (Myocyte sequestration and myocyte isolation) The Cardiovascular Continuum: Mechanisms and Mediators Oxidative Target Organ Stress/Endothelial Myocardial Pathological Tissue Injury Tissue Loss Damage Dysfunction Infarction Remodeling VascularCAD Disease TargetVentricular Organ DysfunctionEnlargement AtherosclerosisVascular DysfunctionHypertrophy HeartEnd-stage Failure Organ Failure Risk Factors: ANGIOTENSIN II Death Clinical Trials with ACE inhibitors MI CONSENSUS, Vascular and CAD ISIS-4, GISSI-3 HOPE, QUIET, SMILE, SAVE EUROPA, PEACE AIRE, TRACE Myocardial Pathological Infarction Remodeling CAD Ventricular Enlargement Atherosclerosis Hypertrophy Heart Failure Hypertension HF SOLVD Risk Factors: CAPPP, ALLHAT Diabetes DM V-HeFT II Hypertension Hyperlipdemia ABCD, REIN, AASK SAVE, Death ATLAS Clinical Trials with ARB DM/Renal Post-MI RENAAL, IDNT VALIANT, IRMAII, ARVAL OPTIMAL ABCD-2V, VAL-PREST NAVIGATOR Myocardial Pathological Infarction Remodeling Ventricular CAD, Nephropathy Enlargement Atherosclerosis Hypertrophy Heart Failure Hypertension HF Risk Factors: SCOPE, Diabetes ELITE I&II Hypertension VALUE, Hyperlipdemia Val-HeFT Death TROPHY, LIFE CHARM Val-Syst Trial: Powerful Double-digit BP Reductions with Valsartan-based Therapy in Patients with ISH Aged 60–80 Randomised, double-blind, titration to effect study of patients (aged 60–80 years) with ISH: 24 weeks’ treatment SBP DBP DIOVAN- Amlodipine- DIOVAN- Amlodipine- based based based based (n=166) (n=163) (n=166) (n=163) 0 –5 –6.0 –6.5 –10 NS –15 Patients were randomised to DIOVAN –20 80 mg or amlodipine 5 mg –25 After 8 weeks, patients with SBP ≥140 mmHg were titrated to DIOVAN –30 160 mg/d or amlodipine 10 mg After an additional 8 weeks, HCTZ 12.5 mg Mean change in BP (mmHg) –35 –33.4 –33.5 NS was added to treatment in patients with SBP ≥140 mmHg Val-Syst: Valsartan in Isolated Systolic Hypertension (ISH); Per protocol population data shown; NS = not significant Clin Ther 2003;25:2765–80 Time Course of Morning BP Changes Mediated by ARBs Morning home BP 165 Patients with essential hypertension: 4 weeks’ treatment 155 145 SBP (mmHg) 135 –7 0 7 14 21 28 Day Start of treatment Valsartan 40–80 mg (n=18) Losartan 25–100 mg (n=18) Telmisartan 10–40 mg (n=18) Candesartan 2–12 mg (n=18) Clin Exp Hypertens 2005;27:477–89 TheThe rolerole ofof arterialarterial stiffnessstiffness The role of arterial stiffness as the major cause of cardio- vascular risk can be seen in recent outcome data. Pulse Wave Velocity aortic pulse wave velocity on entry was used to stratify arterial stiffness in a cohort of ESRD patients into tertiles 1st tertile has almost normal results; 3rd tertile has 6x risk of “all cause’ mortality Clin Exp Hypertens. 2004 Oct-Nov;26(7-8):689-99 Reduces Arterial Stiffness Randomised study of patients with hypertension: 3 months’ treatment Nifedipine 20 mg (n=20) Diovan 80 mg (n=21) 0 –50 –100 –69 –150 –200 p=0.02 Brachial–ankle PWV* (cm/sec) –250 –195 *Brachial-ankle pulse wave velocity (PWV), a measure for systemic arterial stiffness Am J Hypertens 2004;17:1050–5 Reduces Arterial Stiffness Randomised, double-blind, parallel-group design study of patients with essential hypertension: 6 weeks’ treatment Diovan 80 mg HCTZ 25 mg Placebo 0 –0.3 –3.2 (n=20) –10 (n=20) from baseline † –20 • Diovan improves arterial compliance in AIx –21.7* patients with hypertension –30 (n=20) • Effects are independent of BP reduction (BP reductions similar for Diovan and HCTZ) Change in –40 †Augmentation index (AIx), a measure of arterial function *p<0.01 vs HCTZ and vs placebo J Hypertens 2002;20:2423–8 DETECTIV : Valsartan Increases Small Artery Elasticity in Asymptomatic Risk Patients with High CV Risk Results from a 12-month study in 76 asymptomatic patients# with RDS ≥6 and controlled BP and cholesterol levels (DETECTIV study) 6 months 12 months 0 77% 3.5 increase* 3.24 -0.5 3 -1 -1.5 2.5 1.51 -2 2 2.39 -2.5 -2.2 1.5 -3 -3.1 1 -3.5 0.55 -3.6 0.5 Change in RDS from baseline -4 44% -3.9 0 reduction* Change in small artery elasticity from baseline (mL/mmHg x100) 6 months 12 months Placebo DIOVAN 160 mg od for 6 months DIOVAN 160 mg od for 12 months #Individuals completing the study with or without antihypertensive or lipid lowering medications, BP <140/90 mmHg; *p<0.000; RDS=Rasmussen Disease Score Duprez et al. JACC 2007;50:published online Val-MARC: Managing BP Aggressively and Evaluating Reductions in hsCRP Multicentre, open-label, randomised, parallel-group study of patients with Stage II hypertension Objectives, to determine: • If BP reduction with DIOVAN/Co-DIOVAN is effective at reducing hsCRP levels • If there is a difference between moderate and aggressive BP reduction in terms of hsCRP change Primary endpoints: • Change in SBP from baseline to Week 6 with DIOVAN vs Co-DIOVAN • Change in hsCRP from baseline to Week 6 with DIOVAN vs Co-DIOVAN • Change in hsCRP from baseline to Week 12 in the overall group DIOVAN 320 mg DIOVAN 320 mg (n=807) (plus optional HCTZ 12.5 mg) DIOVAN 160 mg (n=836) Screening 0–7 days Co-DIOVAN 160/12.5 mg (n=832) Co-DIOVAN 320/12.5 mg Co-DIOVAN 320/12.5mg (n=808) (or optional Co-DIOVAN 320/25mg) Week 0 Week 2 Week 6 Week 12 Visit 1 Visit 2 Visit 3 Visit 4 (randomisation) (End of study) Hypertension 2006;48:73-79 Val-MARC : DIOVAN Reduces hsCRP Levels Independent of Blood Pressure Reduction Results from a 6-week study* in 1,615 patients with stage II HTN# (Val-MARC study) 6 4.4% 4 2 0 -2 -4 -6 from baseline to 6 weeks* -8 -10 Change in hsCRP plasma level (%) -8.9% DIOVAN Co-DIOVAN 160 - 320 mg od 160/12.5 - 320/12.5 mg od (n=807, median change -0.12) (n=808, median change +0.05) #SBP ≥160 mmHg or DBP ≥100 mmHg, patients completing the study; *Study duration 12 weeks, after 6 weeks of treatment, HCTZ 12.5 mg/day allowed at discretion in both groups to reach BP <140/90 mmHg); p<0.001 for DIOVAN vs. Co-DIOVAN Ridker et al. Hypertension 2006;48:73-79 VALUE: Elective Titration to Target BP(<140/90 mmHg) Patients aged ≥50 years, with treated or untreated hypertension DIOVAN 160 mg + and at high risk of CV events HCTZ 25 mg + ‘Free’ add-on Co-DIOVAN DIOVAN-based Co-DIOVAN 160/25 mg regimen 160/12.5 mg DIOVAN 160 mg DIOVAN 80 mg Rollover from previous therapy Amlo 5 mg (92%) Amlo 10 mg Amlodipine- Amlo 10 mg + based regimen HCTZ 12.5 mg Amlo 10 mg + HCTZ 25 mg Amlo 10 mg + HCTZ 25 mg + ‘Free’ add-on Month –0.5 0 1 2 3 4 6 * 72 Screening Randomisation End of treatment adjustment period *Patient visits every 6 months for Months 6–72; Amlo = amlodipine Lancet 2004;363:2022–31 VALUE: Rate of Cardiac Events Did not Differ Between the Vasarta and Amlodipine Groups 14 DIOVAN-based regimen 12 Amlodipine-based regimen 10 8 6 first event (%) event first 4 Proportion of patients with 2 HR=1.03; 95% CI=0.94–1.14; p=0.49 0 0 6 12 18 24 30 36 42 48 54 60 66 Number at risk Time (months) DIOVAN 7,649 7,459 7,407 7,250 7,0856,906 6,732 6,5366,349 5,911 3,765 1,474 Amlodipine 7,596 7,469 7,424 7,267 7,1176,955 6,772 6,5766,391 5,959 3,725 1,474 Lancet 2004;363:2022–31 LIFE : The Losartan Intervention For Endpoint Reduction in Hypertension Study Patients aged ≥55 years, with treated or untreated hypertensionand at high risk of CV events * Titration to target blood pressure: <140 / 90 mmHg Losartan 100 mg + HCTZ 12.5- 25 mg + others** Losartan 100 mg + HCTZ 12.5 mg* Losartan 50 mg + HCTZ 12.5 mg* Placebo Losartan 50 mg Atenolol 50 mg Atenolol 50 mg + HCTZ 12.5 mg* Atenolol 100 mg + HCTZ 12.5 mg* Atenolol 100 mg + HCTZ 12.5- 25mg + others** Day Day Day Mth Mth Mth Mth Yr Yr Yr Yr Yr Yr Yr Yr −14 −7 1 1 2 4 6 1 1.5 2 2.5 3 3.5 4 5 * Titration encouraged if SiDBP >90 mmHg or SiSBP >140 mmHg but was mandatory if SiBP >160 / 95 mmHg **Other antihypertensives excluding ACEIs, A II antagonists, beta blockers Lancet 2002;359;995-1003-1010 LIFE : BP reductions 180 Atenolol Losartan 160 Systolic 140 120 100 Mean arterial mmHg 80 Diastolic
Load more

Recommended publications
  • Cough Induced by Enalapril but Not by Captopril
    Eur Respir J 1989, 2, 289-291 CASE REPORT Cough induced by enalapril but not by captopril H. Puolijoki*, M. Nieminen*, E. Moilanen**, L. Siitonen*, A. Lahdensuo*, P. Reinikainen*, H. Vapaatalo** Cough iruluced by enalapril but 1101 by capropril. H. Puolijoki, M Nieminen, •Tampere University Central Hospital. E. Moilanen, L. Siironen, A. Lahdensuo, P. Reinikainen, If. VapaaJalo. •• Dept of Biomedical Sciences, University of ABSTRACT: We report a 68 yr old woman with hypertension wbo Tampcre. Finland. developed a dry cough on enalaprll but not on captopril therapy. Pul­ monary function te!its, methacholine in halation challenges, total blood Correspondence: H. Puolijoki, Dept of Pulmonary Diseases, Turlcu University Central Hospital, SF- eoslnophiJ counts, and changes In plasma concentrations or prostaglandin 207 40 Preitila, Finland. E2 and tllromboxane 81 did not explain the difference in the adverse reaction between tbese two angiotensin converting enzyme inhibitors. Keywords: ACE inhibitors; captopril; cough; Eur Respir J., 1989, 2, 289- 291. enalapril. Received: March, 1988; accepted after revision August 9, 1988. Angiotensin converting enzyme (ACE) inhibiLors like Case History capropril and ena1april are usually well tolerated. How­ ever, in some patientS they may cause cough as an A 68 yr old non-smoking woman with diabetes, adverse reaction [1]. We report a female patiem who hypertension and compensated heart failure, but with developed a cough on enalapril but not on captopril no respiratory disease or abnormalities on chest X-ray, therapy. We evaluated her lung function, bronchial re­ developed a dry cough but no dyspnoea or posrnasal activity to methacholine, LolaJ blood eosinophi l count as drip during Lreatmem with ena1april (Renitcc®, MSD, E 20 mg·day·1) for hypertension.
    [Show full text]
  • Ace Inhibitors (Angiotensin-Converting Enzyme)
    Medication Instructions Ace Inhibitors (Angiotensin-Converting Enzyme) Generic Brand Benazepril Lotensin Captopril Capoten Enalapril Vasotec Fosinopril Monopril Lisinopril Prinivil, Zestril Do not Moexipril Univasc Quinapril Accupril stop taking Ramipril Altace this medicine Trandolapril Mavik About this Medicine unless told ACE inhibitors are used to treat both high blood pressure (hypertension) and heart failure (HF). They block an enzyme that causes blood vessels to constrict. This to do so allows the blood vessels to relax and dilate. Untreated, high blood pressure can damage to your heart, kidneys and may lead to stroke or heart failure. In HF, using by your an ACE inhibitor can: • Protect your heart from further injury doctor. • Improve your health • Reduce your symptoms • Can prevent heart failure. Generic forms of ACE Inhibitors (benazepril, captopril, enalapril, fosinopril, and lisinopril) may be purchased at a lower price. There are no “generics” for Accupril, Altace Mavik, and of Univasc. Thus their prices are higher. Ask your doctor if one of the generic ACE Inhibitors would work for you. How to Take Use this drug as directed by your doctor. It is best to take these drugs, especially captopril, on an empty stomach one hour before or two hours after meals (unless otherwise instructed by your doctor). Side Effects Along with needed effects, a drug may cause some unwanted effects. Many people will not have any side effects. Most of these side effects are mild and short-lived. Check with your doctor if any of the following side effects occur: • Fever and chills • Hoarseness • Swelling of face, mouth, hands or feet or any trouble in swallowing or breathing • Dizziness or lightheadedness (often a problem with the first dose) Report these side effects if they persist: • Cough – dry or continuing • Loss of taste, diarrhea, nausea, headache or unusual fatigue • Fast or irregular heartbeat, dizziness, lightheadedness • Skin rash Special Guidelines • Sodium in the diet may cause you to retain fluid and increase your blood pressure.
    [Show full text]
  • Angiotensin-Converting Enzyme (ACE) Inhibitors
    Angiotensin-Converting Enzyme (ACE) Inhibitors Summary Blood pressure reduction is similar for the ACE inhibitors class, with no clinically meaningful differences between agents. Side effects are infrequent with ACE inhibitors, and are usually mild in severity; the most commonly occurring include cough and hypotension. Captopril and lisinopril do not require hepatic conversion to active metabolites and may be preferred in patients with severe hepatic impairment. Captopril differs from other oral ACE inhibitors in its rapid onset and shorter duration of action, which requires it to be given 2-3 times per day; enalaprilat, an injectable ACE inhibitor also has a rapid onset and shorter duration of action. Pharmacology Angiotensin Converting Enzyme Inhibitors (ACE inhibitors) block the conversion of angiotensin I to angiotensin II through competitive inhibition of the angiotensin converting enzyme. Angiotensin is formed via the renin-angiotensin-aldosterone system (RAAS), an enzymatic cascade that leads to the proteolytic cleavage of angiotensin I by ACEs to angiotensin II. RAAS impacts cardiovascular, renal and adrenal functions via the regulation of systemic blood pressure and electrolyte and fluid balance. Reduction in plasma levels of angiotensin II, a potent vasoconstrictor and negative feedback mediator for renin activity, by ACE inhibitors leads to increased plasma renin activity and decreased blood pressure, vasopressin secretion, sympathetic activation and cell growth. Decreases in plasma angiotensin II levels also results in a reduction in aldosterone secretion, with a subsequent decrease in sodium and water retention.[51035][51036][50907][51037][24005] ACE is found in both the plasma and tissue, but the concentration appears to be greater in tissue (primarily vascular endothelial cells, but also present in other organs including the heart).
    [Show full text]
  • Hyponatremia Induced by Angiotensin Converting Enzyme Inhibitors and Angiotensin
    DOI: 10.7860/JCDR/2018/31983.11754 Original Article Hyponatremia Induced by Angiotensin Converting Enzyme Inhibitors and Angiotensin Pharmacology Section Receptor Blockers-A Pilot Study S BHUVANESHWARI1, PRAKASH VEL SANKHYA SAROJ2, D VIJAYA3, M SABARI SOWMYA4, R SENTHIL KUMAR5 ABSTRACT Results: Among all, 48% (24 out of 50) of the study population Introduction: Hyponatremia, serum sodium <135 mmol/L, can administered with ACEI and ARB developed hyponatremia. result in neurological manifestation in acute cases, may lead Predisposition to develop hyponatremia was high in males to seizures and coma. Angiotensin Converting Enzyme Inhibitor compared to females. Incidence of hyponatremia was 62.5% (10 (ACEI) and Angiotensin II Receptor Blockers (ARB) are drugs out of 16) in the age group of 56-75 years. Though, incidence of that have been commonly prescribed for the treatment of hyponatremia was 54.5% (18 out of 33) in ACEI group compared hypertension and cardiac diseases. It has become important to 35.2% (6 out of 17) in ARB group, but it was not statistically to evaluate and investigate the incidence of hyponatremia on significant. The study also revealed that metosartan had a higher consumption of these drugs. association with hyponatremia compared to other drugs. Aim: To determine the susceptibility of patients on ACEI and Conclusion: Hyponatremia was induced in nearly 50% of ARB to hyponatremia and to ascertain the drug producing patients taking ACEI and ARB. The incidence of hyponatremia notable hyponatremia among ACEI and ARB. among patients on these two drugs did not show statistical variation. Metosartan showed a higher incidence of Materials and Methods: The study was conducted in a tertiary hyponatremia compared to enalapril, ramipril, captopril, care hospital.
    [Show full text]
  • 5 Mg Film-Coated Tablets [Nationally Completed Name] 10 Mg Film-Coated Tablets [Nationally Completed Name] 20 Mg Film-Coated Tablets
    SUMMARY OF PRODUCT CHARACTERISTICS 1. NAME OF THE MEDICINAL PRODUCT [nationally completed name] 5 mg film-coated tablets [nationally completed name] 10 mg film-coated tablets [nationally completed name] 20 mg film-coated tablets 2. QUALITATIVE AND QUANTITATIVE COMPOSITION One film-coated tablet contains 5/10/20 mg Benazepril hydrochloride. For the full list of excipients see section 6.1 3. PHARMACEUTICAL FORM Film-coated tablet [nationally completed name] 5 mg film-coated tablets: Oval (4 x 8 mm), light yellow film-coated tablets with score on both sides. [nationally completed name] 10 mg film-coated tablets: Oval (11 x 5.5 mm) yellow film-coated tablets with score on both sides. [nationally completed name] 20 mg film-coated tablets: Oval (11 x 5.5 mm) light red film-coated tablet with score on both sides. The tablet can be divided into equal doses. 4. CLINICAL PARTICULARS 4.1 Therapeutic indications Essential hypertension, congestive heart failure - in addition to diuretics and especially to digitalis glycosides in cases of severe congestive heart failure 4.2 Posology and method of administration Posology Paediatric population [nationally completed name] is not recommended for use in children due to insufficient data on safety and efficacy (see section 4.4). Essential hypertension 10 to 20 mg daily divided in one or two doses. Maximum daily dose is 40 mg. Congestive heart failure Initially 2.5 mg daily. After 2-4 weeks the dosage can be increased to 5 mg daily. Maximum dose is 20 mg daily. Dosage at renal impairment For the treatment of essential hypertension the dose should be reduced if creatinine clearance is below 30 ml/min.
    [Show full text]
  • Switching Ace-Inhibitors
    Switching Ace-inhibitors http://www.ksdl.kamsc.org.au/dtp/switching_ace_inhibitors.html Change to → Enalapril Quinapril Ramipril Change from ↓ (Once daily dosing) (Once daily dosing) (Once daily dosing) Captopril Captopril 12.5mg daily Enalapril 2.5mg1 Quinapril 2.5mg Ramipril 1.25mg Captopril 25mg daily Enalapril 5mg1 Quinapril 5mg Ramipril 1.25-2.5mg Captopril 50mg daily Enalapril 7.5mg1 Quinapril 10mg Ramipril 2.5-5mg Captopril 100mg daily Enalapril 20mg1 Quinapril 20mg Ramipril 5-10mg2 Captopril 150mg daily Enalapril 40mg Quinapril 40mg Ramipril 10mg Fosinopril Fosinopril 5mg daily Enalapril 5mg Quinapril 5mg Ramipril 1.25mg Fosinopril 10mg daily Enalapril 10mg Quinapril 10mg Ramipril 2.5mg Fosinopril 20mg daily Enalapril 20mg Quinapril 20mg Ramipril 5mg Fosinopril 40mg daily Enalapril 40mg Quinapril 40mg Ramipril 10mg Lisinopril Lisinopril 5mg daily Enalapril 5mg Quinapril 5mg Ramipril 1.25mg Lisinopril 10mg daily Enalapril 10mg Quinapril 10mg Ramipril 2.5mg Lisinopril 20mg daily Enalapril 20mg Quinapril 20mg Ramipril 5mg Lisinopril 40mg Enalapril 40mg Quinapril 40mg Ramipril 10mg Perindopril Perindopril 2mg daily Enalapril 5-10mg Quinapril 5-10mg Ramipril 2.5mg Perindopril 4mg daily Enalapril 10mg-20mg Quinapril 10mg-20mg Ramipril 5mg Perindopril 8mg daily Enalapril 20-40mg Quinapril 20-40mg Ramipril 10mg Trandolapril Trandolapril 0.5mg d Enalapril 5mg Quinapril 5mg Ramipril 1.25mg Trandolapril 1mg daily Enalapril 10mg Quinapril 10mg Ramipril 2.5mg Trandolapril 2mg daily Enalapril 20mg Quinapril 20mg Ramipril 5mg Trandolapril 4mg daily Enalapril 40mg Quinapril 40mg Ramipril 10mg There are few studies comparing equivalent doses of ACE-inhibitors, for specific indications. Therefore, the above recommendations are based on clinical experiences and are not specific for any indication.
    [Show full text]
  • ACE2 As a Therapeutic Target for COVID-19; Its Role in Infectious Processes and Regulation by Modulators of the RAAS System
    Journal of Clinical Medicine Review ACE2 as a Therapeutic Target for COVID-19; Its Role in Infectious Processes and Regulation by Modulators of the RAAS System Veronique Michaud 1,2, Malavika Deodhar 1, Meghan Arwood 1, Sweilem B Al Rihani 1, Pamela Dow 1 and Jacques Turgeon 1,2,* 1 Tabula Rasa HealthCare Precision Pharmacotherapy Research & Development Institute, Orlando, FL 32827, USA; [email protected] (V.M.); [email protected] (M.D.); [email protected] (M.A.); [email protected] (S.B.A.R.); [email protected] (P.D.) 2 Faculty of Pharmacy, Université de Montréal, Montreal, QC H3C 3J7, Canada * Correspondence: [email protected]; Tel.: +856-938-8793 Received: 11 June 2020; Accepted: 2 July 2020; Published: 3 July 2020 Abstract: Angiotensin converting enzyme 2 (ACE2) is the recognized host cell receptor responsible for mediating infection by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). ACE2 bound to tissue facilitates infectivity of SARS-CoV-2; thus, one could argue that decreasing ACE2 tissue expression would be beneficial. However, ACE2 catalytic activity towards angiotensin I (Ang I) and II (Ang II) mitigates deleterious effects associated with activation of the renin-angiotensin-aldosterone system (RAAS) on several organs, including a pro-inflammatory status. At the tissue level, SARS-CoV-2 (a) binds to ACE2, leading to its internalization, and (b) favors ACE2 cleavage to form soluble ACE2: these actions result in decreased ACE2 tissue levels. Preserving tissue ACE2 activity while preventing ACE2 shredding is expected to circumvent unrestrained inflammatory response. Concerns have been raised around RAAS modulators and their effects on ACE2 expression or catalytic activity.
    [Show full text]
  • Angiotensin Modulators: ACE Inhibitors and Direct Renin Inhibitors Review 10/09/2008
    Angiotensin Modulators: ACE Inhibitors and Direct Renin Inhibitors Review 10/09/2008 Copyright © 2004 - 2008 by Provider Synergies, L.L.C. All rights reserved. Printed in the United States of America. All rights reserved. No part of this publication may be reproduced or transmitted in any form or by any means, electronic or mechanical, including photocopying, recording, digital scanning, or via any information storage and retrieval system without the express written consent of Provider Synergies, L.L.C. All requests for permission should be mailed to: Attention: Copyright Administrator Intellectual Property Department Provider Synergies, L.L.C. 5181 Natorp Blvd., Suite 205 Mason, Ohio 45040 The materials contained herein represent the opinions of the collective authors and editors and should not be construed to be the official representation of any professional organization or group, any state Pharmacy and Therapeutics committee, any state Medicaid Agency, or any other clinical committee. This material is not intended to be relied upon as medical advice for specific medical cases and nothing contained herein should be relied upon by any patient, medical professional or layperson seeking information about a specific course of treatment for a specific medical condition. All readers of this material are responsible for independently obtaining medical advice and guidance from their own physician and/or other medical professional in regard to the best course of treatment for their specific medical condition. This publication, inclusive of all forms contained herein, is intended to be educational in nature and is intended to be used for informational purposes only. Comments and suggestions may be sent to [email protected].
    [Show full text]
  • Drug Class Review on Angiotensin Converting Enzyme Inhibitors
    Drug Class Review on Angiotensin Converting Enzyme Inhibitors Final Report June 2004 Roger Chou, MD Mark Helfand, MD, MPH Susan Carson, MPH Oregon Evidence-based Practice Center Oregon Health & Science University Mark Helfand, MD, MPH, Director Final Report Drug Effectiveness Review Project Table of contents Click the bookmarks tab on the left side of the screen to navigate through this report without scrolling Introduction..……………………………………………………………………………...4 Scope and key questions………………………………………………………………….4 Methods…………………………………………………………………………………...6 Study Selection…………………………………………………………………….6 Data Abstraction…………………………………………………………………...8 Validity Assessment ………………………………………………………………8 Data Synthesis ……………………………………………………………………..9 Results……………………………………………………………………………………..9 Key Question 1: For adult patients with various indications, Do angiotensin converting enzyme inhibitors differ in efficacy?………………….9 1a. Hypertension……………………………………………………………9 1b. High cardiovascular risk……………………………………………….12 1c. Recent myocardial infarction…………………………………………..14 1d. Heart failure……………………………………………………………18 1e. Diabetic and nondiabetic nephropathy………………………………...23 Key Question 2: For adult patients with various indications, Do angiotensin converting enzyme inhibitors differ in adverse effects?…………..24 Key Question 3: Are there subgroups for which one angiotensin converting Enzyme inhibitor is more effective or associated with fewer adverse events?…….26 Summary…………………………………………………………………………………..28 References…………………………………………………………………………………33 Figure 1. Literature
    [Show full text]
  • COMPARISON of the EFFECTS of CAPTOPRIL and VALSARTAN on HEART RATE VARIABILITY in HEALTHY MEN
    COMPARISON of the EFFECTS of CAPTOPRIL and VALSARTAN on HEART RATE VARIABILITY in HEALTHY MEN Dayimi KAYA MD, Ali Metin ESEN MD, İrfan BARUTÇU MD, Ataç ÇELİK MD Celal KİLİT MD, Ersel ONRAT MD Department of Cardiology, School of Medicine, Afyon Kocatepe University, Afyon,Turkey Summary Objective: Angiatensin ll is well known to have several effects on cardiovascular autonomicfunctions. However; ılıere is no data regarding the lıead to lıead comparison of the effect of angiatensin canverıing enzynıe (ACE) inlıibitors and angiatensin receptar blockers, the major drugs to inhibit angiatensin Il, on heart rate variabiliry (HRV). The aim of this study is to conıpare the effects ofa single dose ACE inhibitor (captopril: 25 mg) and an angiatensin receptar bloeker (valsartan: 80 mg) on HRV paranıeters. Material and Methods: The effects of a single oral dose of captopril, vatsartan and placebo on 9 healthynıale individuals (nıean age 28±2 years) were studied ina double blind crossover placebo control/ed study on three occasions. Frequency and time domain paranıeters of HRV were measured during supine position and during handgrip exercise bejare and after taking each age1ıt. Results: Baseline blood pressure values, he art rates and HRV parameters w ere not fo und statistically different on each occasion. With captopril but not vaZsartan administration, heart ra te at supine position decrectsed significantly in comparison with the baseline valııes without a change in HRV paranıeters (865±33 vs. 917±39, p=0.038). When compared to placebo during handgrip exercise, captopril caused a significant increase in the standard deviation of R-R interval (SDNN), whiclı isa global HRV marker (50±5 ms vs.
    [Show full text]
  • Dosing of ACE-Inhibitors and Arbs
    Dosing of ACE-Inhibitors and ARBs Drug Name Starting Dose3 Goal Dose in CKD3 Dosing in renal dysfunction 1,2,4 ACE-Inhibitors Benazepril (Lotensin) 10 mg daily 20-40 mg/d in CrCl < 30 mL/minute or patients taking diuretics, start 5 1-2 divided doses mg/day. Captopril (Capoten) 6.25-25 mg 25-150 mg Reduce initial dose and use smaller increments to titrate three times per day 2 or 3 times per day at 1-2 week intervals. Then, back-titrate to lowest effective dose. CrCl 10—50 ml/min: reduce recommended dose by 25%. CrCl < 10 ml/min: reduce recommended dose by 50%. Removed by hemodialysis; consider giving a dose within 4 hours after dialysis. Diabetic nephropathy (proteinuria >500 mg/day in type 1 diabetics with retinopathy): 25 mg TID Enalapril (Vasotec) 5 mg daily 10-40 mg daily in HTN: Start with 2.5 mg/day if CrCL <= 30 mL/minute; 1-2 divided doses 2.5 mg on dialysis day in hemodialysis patients (dose on non-dialysis days based on BP) CHF: Start with 2.5mg/day under close supervision if serum Na <130 mEq/L or serum Cr>1.6 mg/dL. May titrate at intervals of =>4 days to 2.5 mg BID, then 5 mg BID and higher as needed to maximum of 40 mg/day. Removed by hemodialysis; consider giving a dose within 4 hours after dialysis. Fosinopril (Monopril) 10 mg daily 20-40 mg daily Dosage adjustment not required; biliary excretion increases in renal dysfunction. Start with 5 mg/day QD in patients with CHF and renal dysfunction.
    [Show full text]
  • Pharmachologic Treatment of Hypertension
    Robert C Orchard MD Types of Hypertension Essential Secondary A disorder of unknown origin affecting the Secondary to other disease processes Blood Pressure regulating mechanisms **************************************************** Environmental Factors Stress Na+ Intake Obesity Smoking Normal Blood Pressure Regulation ! Hydraulic equation: Blood Pressure = Cardiac output (CO) X Resistance to passage of blood through precapillary arterioles (PVR) ! Physiologically CO and PVR is maintained minute to minute by – arterioles (1) postcapillary venules (2) and Heart (3) ! Kidney is the fourth site – volume of intravascular fluid ! Baroreflex, humoral mechanism and renin-angiotensin- aldosterone system regulate the above 4 sites ! Local agents like Nitric oxide ! In hypertensives – Baroreflex and renal blood-volume control system – set at higher level ! All anti-hypertensives act via interfering with normal mechanisms Antihypertensive Drugs ! Diuretics: ! Thiazides: Hydrochlorothiazide, chlorthalidone ! High ceiling: Furosemide ! K+ sparing: Spironolactone,eplerenone, triamterene and amiloride MOA: Acts on Kidneys to increase excretion of Na and H2O – decrease in blood volume – decreased BP ! Angiotensin-converting Enzyme (ACE) inhibitors: ! Captopril, lisinopril., enalapril, ramipril, fosinopril etc MOA: Inhibit synthesis of Angiotensin II – decrease in peripheral resistance and blood volume ! Angiotensin (AT1) blockers: ! Losartan, candesartan, valsartan, telmisartan etc MOA: Blocks binding of Angiotensin II to its receptors Antihypertensive
    [Show full text]